stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. MGNX
    stockgist
    HomeTop MoversCompaniesConcepts
    MGNX logo

    MacroGenics, Inc.

    MGNX
    NASDAQ
    Healthcare
    Biotechnology
    Rockville, MD, US341 employeesmacrogenics.com
    $3.06
    +0.17(5.69%)

    Mkt Cap $195M

    $1.10
    $3.43

    52-Week Range

    At a Glance

    AI-generated

    MacroGenics, Inc.

    Revenue breakdown: Revenues From License Agreements (47.2%), Revenue From Collaborative Agreements (29.3%), Contract Manufacturing (9.3%).

    8-K
    MacroGenics, Inc. announced financial and operating results as of and for the year ended December 31, 2025, via press release dated March 9, 2026. The filing includes Exhibit 99.1 detailing these results and Exhibit 104 for cover page interactive data.

    $195M

    Market Cap

    $150M

    Revenue

    -$75M

    Net Income

    Employees341
    Fundamentals

    How The Business Makes Money

    Revenue by Segment

    Revenues From License Agreements47.2%($383M)
    Revenue From Collaborative Agreements29.3%($238M)
    Contract Manufacturing9.3%($76M)
    Revenues From CMO Agreements Member7.1%($58M)
    Product4.2%($34M)
    Manufacturing Services1.6%($13M)
    Revenue From Royality Agreements Member1.3%($11M)
    Activity

    What Changed Recently

    Financial Results
    Mar 8, 2026

    Results of Operations and Financial Condition On March 9, 2026, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the ye

    Other Event
    Mar 1, 2026

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 2

    Other Event
    Feb 23, 2026

    . Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release dated February 23 , 202 6 104 Cover Page In

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    OVIDOvid Therapeutics Inc.$2.19+1.62%$332M-12.0
    STTKShattuck Labs, Inc.$6.43+2.96%$308M-13.0
    CNTXContext Therapeutics Inc.$2.73+3.02%$251M-10.9
    ZNTLZentalis Pharmaceuticals,...$2.63+2.14%$186M-1.2
    CNTBConnect Biopharma Holding...$3.00+10.48%$168M-4.5
    WHWKWhitehawk Therapeutics In...$3.50-1.13%$165M-12.3
    ORMPOramed Pharmaceuticals In...$3.43+1.18%$139M3.4
    COYACoya Therapeutics, Inc.$4.02-1.47%$67M-3.3
    Analyst View
    Company Profile
    CIK0001125345
    ISINUS5560991094
    CUSIP556099109
    Phone301 251 5172
    Address9704 Medical Center Drive, Rockville, MD, 20850, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice